未登录

J

Jenna Burke

regenxbio inc.

H指数:10

被引数:1,276

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-in-human intracisternal dosing of RGX-111 in severe MPS I is well-tolerated and generates sustained neurodevelopment without HSCT

RGX-111在严重MPS I中的首次人体脑池内给药耐受性良好且无需HSCT即可产生持续神经发育

Molecular Therapy

IF12

2026-04-100

OAAI

RGX-381: Interim results from the first-in-human clinical trial of an investigational gene therapy for the treatment of ocular manifestations of CLN2 Batten disease

MOLECULAR GENETICS AND METABOLISM

IF3.5

2024-02-010

PRE

First in-human, intracisternal dosing of RGX-111, an investigational AAV gene therapy, for a 21-month-old child with mucopolysaccharidosis type I (MPS I): 3.5 year follow-up

MOLECULAR GENETICS AND METABOLISM

IF3.5

2024-02-011

PRE

Interim results from the first-in-human intracisternal dosing of RGX-181 investigational AAV9 gene therapy in a child with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2)

MOLECULAR GENETICS AND METABOLISM

IF3.5

2024-02-010

PRE

The Disclosure and Consequences of US Critical Audit Matters

美国关键审计事项的披露及后果

ACCOUNTING REVIEW

IF4.4

2023-03-1741

PRE

RGX-111 GENE THERAPY FOR THE TREATMENT OF SEVERE MUCOPOLYSACCHARIDOSIS TYPE I (MPS I): INTERIM ANALYSIS OF DATA FROM THE FIRST IN HUMAN STUDY

MOLECULAR GENETICS AND METABOLISM

IF3.5

2023-03-010

PRE

RGX-111 gene therapy for the treatment of severe mucopolysaccharidosis type I (MPS I): Interim analysis of data from the first in human study

MOLECULAR GENETICS AND METABOLISM

IF3.5

2023-02-010

PRE

The costs and benefits of retirement policies at US audit firms

JOURNAL OF ACCOUNTING AND PUBLIC POLICY

IF2.2

2021-07-019

PREAI

Do Boards Take Environmental, Social, and Governance Issues Seriously? Evidence from Media Coverage and CEO Dismissals

JOURNAL OF BUSINESS ETHICS

IF6.7

2021-01-08103

PREAI

The Use and Characteristics of Foreign Component Auditors in US Multinational Audits: Insights from FormAPDisclosures

外国组成部分审计师在美国跨国审计中的使用和特点: 来自形式披露的见解

CONTEMPORARY ACCOUNTING RESEARCH

IF3.8

2020-10-2033

PREAI

The Heterogeneity of Board-Level Sustainability Committees and Corporate Social Performance

董事会可持续发展委员会的异质性与企业社会绩效

JOURNAL OF BUSINESS ETHICS

IF6.7

2017-02-03141

PREAI

The business case for integrated reporting: Insights from leading practitioners, regulators, and academics

综合报告的商业案例: 来自领先从业者、监管机构和学者的见解

BUSINESS HORIZONS

IF7

2016-05-01109

PREAI